EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 11 (Novembre 2025) Med Sci (Paris), 41 11 (2025) 869-876 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 11, Novembre 2025
Page(s) 869 - 876
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025185
Published online 12 December 2025
  1. Chen C, Haupert SR, Zimmermann L, et al. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022 ; 226 :1593–607. [Google Scholar]
  2. Al-Aly Z, Rosen C. J. Long covid and impaired cognition—more evidence and more work to do. N Engl J Med 2024 ; 390 : 858–60. [Google Scholar]
  3. Scurati R, Papini N, Giussani P, et al. The challenge of Long COVID-19 management: from disease molecular hallmarks to the proposal of exercise as therapy. IJMS 2022 ; 23 : 12311. [Google Scholar]
  4. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med 2023 ; 29 : 2347–57. [Google Scholar]
  5. Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. J Med Vir 2023 ; 95 : e28852. [Google Scholar]
  6. Kozłowski P, Leszczyn ΄ska A, Ciepiela O. Long COVID definition, symptoms, risk factors, epidemiology and autoimmunity: a narrative review. AJM Open 2024 ; 11:100068. [Google Scholar]
  7. Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med 2021 ; 268 : 113426. [Google Scholar]
  8. Pasini E, Corsetti G, Romano C, et al. Serum Metabolic Profile in Patients With Long-Covid (PASC) Syndrome: Clinical Implications. Front Med 2021; 22 ; 8:714426. [Google Scholar]
  9. Altmann DM, Whettlock EM, Liu S, et al. The immunology of long COVID. Nat Rev Immunol 2023 ; 3 :618–34. [Google Scholar]
  10. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023 ; 21:133–46. [CrossRef] [PubMed] [Google Scholar]
  11. Wei X, Qian W, Narasimhan H, et al. Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae. Science 2025 ; 387: eadq2509. [Google Scholar]
  12. Sariol A & Perlman S. Lung inflammation drives Long Covid. Science 2025 ; 387 : 1039–40. [Google Scholar]
  13. Fekete M, Lehoczki A, Szappanos Á, et al. Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. GeroScience 2025 1–35. [Google Scholar]
  14. Zhang L, Huang T, He H, et al. Unraveling the molecular mechanisms of Ace2-mediated post-COVID-19 cognitive dysfunction through systems genetics approach. Exp Neurol 2024 ; 381: 114921. [Google Scholar]
  15. Malioukis A, Snead R S, Marczika J, et al. Pathophysiological, neuropsychological, and psychosocial influences on neurological and neuropsychiatric symptoms of post-acute covid-19 syndrome: impacts on recovery and symptom persistence. Biomedicines 2024 ; 12 : 2831. [Google Scholar]
  16. Titze-de-Almeida R, Lacerda PHA, de Oliveira EP, et al. Sleep and memory complaints in long COVID: An insight into clustered psychological phenotypes. PeerJ 2024. 12, e16669. [Google Scholar]
  17. Popa E, Popa A E, Poroch M, et al. The molecular mechanisms of cognitive dysfunction in long covid: a narrative Review. Inter J Mol Sci 2025 ; 26: 5102. [Google Scholar]
  18. Panagea E, Messinis L, Petri M C, et al. Neurocognitive impairment in long COVID: a systematic review. Arch Clin Neuropsy 2025; 40 : 125–49. [Google Scholar]
  19. Plant AN, Rasheed AZ, Hasan M. Long COVID and the brain: a retrospective study of the neuropsychological manifestations of Long COVID. COVID 2025; 5(5): 65. [Google Scholar]
  20. Fekete R, Simats A, Bíró E, et al. Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1-and IL-6-related systemic inflammation in COVID-19. Nat Neurosci 2025; 1–19. [Google Scholar]
  21. Kumar S, Bhatia Z, Seshadri S. Microbiome and mycobiome cross-talk from an immunobiotic perspective in COVID-19 and post-acute COVID-19 syndrome. Exp Immuno 2025 ; 5:1003182. [Google Scholar]
  22. Zhang D, Zhou Y, Ma Y, et al. Gut microbiota dysbiosis correlates with long COVID-19 at one-year after discharge. Korean Med 2023; 38: e120. [Google Scholar]
  23. Qiu Y, Mo C, Chen L, et al. Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions. Med Comm 2024; 5: e513. [Google Scholar]
  24. Piazzesi A, Pane S, Del Chierico F, et al. The pediatric gut bacteriome and virome in response to sars-cov-2 infection. Front Cell Infect Microbiol 2024 ; 14:1335450. [Google Scholar]
  25. Barichello T, Kluwe-Schiavon B, Borba LA, et al. Alterations in Gut Microbiome Composition and Increased Inflammatory Markers in Post-COVID-19 Individuals. Mol Neurobio 2025; 1–10. [Google Scholar]
  26. Yousef M, Rob M, Varghese S, et al. The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review. Life Sci 2024, 122535. [Google Scholar]
  27. Lupi L, Vitiello A, Parolin C, et al. The potential role of viral persistence in the post-acute sequelae of SARS-CoV-2 infection (PASC). Pathogens 2024; 13: 388. [Google Scholar]
  28. Gheorghita R, Soldanescu I, Lobiuc A, et al. The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches. Front Immunol 2024 ; 15: 1344086. [Google Scholar]
  29. Peluso M J, Deeks S G. Mechanisms of long COVID and the path toward therapeutics. Cell 2024; 187: 5500–29. [Google Scholar]
  30. Molnar T, Lehoczki A, Fekete M, et al. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. Geroscience 2024; 46: 5267–86. [Google Scholar]
  31. Polli A, Godderis L, Martens D S, et al. Exploring DNA methylation, telomere length, mitochondrial DNA, and immune function in patients with Long-COVID. BMC Med 2025 ; 23: 60. [Google Scholar]
  32. Majima H J, Chatatikun M, Indo H P, et al. Lipidated COVID-19 localizes into mitochondria and causes oxidative damage to mitochondrial dna–pathophysiology of long COVID. Med Res Arch 2025; 13. [Google Scholar]
  33. Gusev E, Sarapultsev A. Exploring the pathophysiology of Long COVID: the central role of low-grade inflammation and multisystem involvement. Inter J Mol Sci 2024; 25: 6389. [Google Scholar]
  34. Kell DB, Khan MA, Kane B, et al. Possible role of fibrinaloid microclots in postural orthostatic tachycardia syndrome (POTS): focus on Long COVID. J Pers Med 2024;14. [Google Scholar]
  35. Beltrán-García J, Osca-Verdegal R, Pallardó FV, et al. Sepsis and coronavirus disease 2019: common features and anti-inflammatory therapeutic approaches. Critical Care Med 2020; 48:1841–4. [Google Scholar]
  36. Zhang S, Chang W, Xie J, et al. The efficacy, safety, and optimal regimen of corticosteroids in sepsis: a bayesian network meta-analysis. Critical Care Expl 2020 ; 2 :e0094. [Google Scholar]
  37. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse covid-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020 ; 159 :481–91. [Google Scholar]
  38. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020 ;79 :859–66. [Google Scholar]
  39. Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med 2020 ; 8 :1106–20. [Google Scholar]
  40. Milne, A., Maskell, S., Sharp, C., Hamilton, F. W., & Arnold, D. T. (2021). Impact of dexamethasone on persistent symptoms of COVID-19: an observational study. medRxiv ; 2021-11. [Google Scholar]
  41. Proal AD, Aleman S, Bomsel M, et al. Targeting the SARS-CoV-2 reservoir in long COVID. Lancet Infec Dis 2025. [Google Scholar]
  42. Stein SR, Ramelli SC, Grazioli A. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022; 612: 758–63. [Google Scholar]
  43. Chakraborty C, Bhattacharya M. The current landscape of long COVID clinical trials: NIH’s RECOVER to Stanford Medicine’s STOP-PASC initiative. Mol Ther Nucleic Acids 2023 ; 33:887–9. [Google Scholar]
  44. Choi YJ, Seo YB, Seo JW, et al. Effectiveness of antiviral therapy on Long COVID: a systematic review and meta-analysis. JCM 2023 ;12:7375. [Google Scholar]
  45. Catalán I P, Buj A G, Muñoz S G, et al. Nirmatrelvir/ritonavir as a possible treatment for Long-COVID. Rev Esp Quim 2023; 36: 545. [Google Scholar]
  46. Durstenfeld M S, Peluso MJ, Lin F, et al. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J Med Viro 2024 ; 96: e29333 [Google Scholar]
  47. Nair M S, Luck M I, Huang Y, et al. Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro. bioRxiv 2023. [Google Scholar]
  48. Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022 ; 399 : 50–9. [Google Scholar]
  49. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Throm aemostasis 2020 ;18 :1094–9. [Google Scholar]
  50. Connors JM, Ariëns RAS. Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Throm Haemo 2023 ; 21 : 2697–701. [Google Scholar]
  51. McCarthy MW. Intravenous immunoglobulin as a potential treatment for long COVID. Exp Opin Biol Ther 2023 ; 23 :1211–7. [Google Scholar]
  52. Morse BA, Motovilov K, Michael Brode W, et al. A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome. Brain Behav Immun 2025 ;123:725–38. [Google Scholar]
  53. Svačina MKR, Sprenger-Svačina A, Tsakmaklis A, et al. The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy. Euro J Neuro 2023 ; 30 : 3551–6. [Google Scholar]
  54. Seibert FS, Stervbo U, Wiemers L, et al. Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun reviews 2023; 22: 103445. [Google Scholar]
  55. Vitari N, Roy S. Intestinal immunoglobulins under microbial dysbiosis: implications in opioid-induced microbial dysbiosis. Front Microbiol 2025; 16:1580661. [Google Scholar]
  56. Scheppke KA, Pepe PE, Jui J, et al. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. Amer J Emer Med 2024 ;75:122–7. [Google Scholar]
  57. Muyldermans S. Nanobodies: natural single-domain antibodies. Ann Rev Biochem 2013 ; 82 : 775–97. [Google Scholar]
  58. Rissiek, B., Koch-Nolte, F., Magnus, T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Cell Neurosci 2014 ; 8 : 344. [Google Scholar]
  59. Alexander E, Leong K W. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J Nanobiotech 2024; 22: 661. [Google Scholar]
  60. Rossotti MA, Bélanger K, Henry KA, et al. Immunogenicity and humanization of single-899 domain antibodies. FEBS J 2022 ; 289: 4304–27. [Google Scholar]
  61. Yu T, Zheng F, He W, et al. Single domain antibody: Development and application in biotechnology and biopharma. Immunol Rev 2024; 328: 98–112. [Google Scholar]
  62. Colas C, Le Berre Y, Fanget M, et al. Physical activity in Long COVID: a comparative study of exercise rehabilitation benefits in patients with Long COVID, coronary artery disease and fibromyalgia. IJERPH 2023 ; 20 : 6513. [Google Scholar]
  63. Gloeckl R, Zwick RH, Fürlinger U, et al. Practical recommendations for exercise training in patients with Long COVID with or without post-exertional malaise: a best practice proposal. Sports Med - Open 2024 ; 10 :47. [Google Scholar]
  64. Nopp S, Moik F, Klok FA, et al. Outpatient pulmonary rehabilitation in patients with Long COVID improves exercise capacity, functional status, dyspnea, fatigue, and quality of life. Respiration 2022 ; 101:593–601. [Google Scholar]
  65. Ghali A, Lacombe V, Ravaiau C, et al. The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome. J Trans Med 2023; 21: 375. [Google Scholar]
  66. Giovanetti M, Pannella G, Altomare A, et al. Exploring the interplay between COVID-19 and gut health: the potential role of prebiotics and probiotics in immune support. Viruses 2024 ; 16 : 370. [Google Scholar]
  67. Morello R, De Rose C, Cardinali S, et al. Lactoferrin as possible treatment for chronic gastrointestinal symptoms in children with Long COVID: case series and literature review. Children 2022 ; 9 :1446. [Google Scholar]
  68. Soltani R, Alikiaie B, Shafiee F, et al. Coenzyme Q10 improves the survival and reduces inflammatory markers in septic patients. BLL 2021;121:154–8. [Google Scholar]
  69. Kim, T. H., Yoon, J., Kim, S., Kang, B. K., Kang, J. W., Kwon, S. Herbal medicines for long COVID: A phase 2 pilot clinical study. Heliyon 2024 ; 10. [Google Scholar]
  70. Nikhat S, Fazil M. Shortening the long-COVID: An exploratory review on the potential of Unani medicines in mitigating post-Covid-19 sequelae. Phytomed Plus 2024 ; 4:100570. [Google Scholar]
  71. Feng BW, Rong PJ. Acupoint stimulation for long COVID: A promising intervention. World J Acupunc - Moxibustion 2023 ; 33 :191–7. [Google Scholar]
  72. Sum CH, Ching JYL, Song T, et al. Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)—A double-blind, randomized, and placebo-controlled clinical trial protocol. Front Med 2023 ; 9 : 990639. [Google Scholar]
  73. Ying X, Jing Z, Yang Y, et al. Investigation of the potential molecular mechanisms of acupuncture in thetreatment of long COVID: a bioinformatics approach. Cell Mol Biol 2024 ; 70 :193–200. [Google Scholar]
  74. Algitany S, Fouad S, Nassif A, et al. The effect of laser acupuncture on immunomodulation and dyspnea in post-COVID-19 patients. areh 2023 ; 37:33–9. [Google Scholar]
  75. Vogel J, Pollack B, Spier E, et al. Designing and optimizing clinical trials for long COVID. Life Sci 2024. 122970. [Google Scholar]
  76. Krumholz HM, Sawano M, Bhattacharjee B, et al. The PAX LC trial: a decentralized, phase 2, randomized, double-blind study of nirmatrelvir/ritonavir compared with placebo/ritonavir for long COVID. Am J Med 2025 ; 138 : 884–92. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.